Presbyopia Epidemiology Forecast 2025-2034

Presbyopia is a universal age-related vision condition, affecting nearly all adults over 45. Its prevalence varies across ethnicities and regions, highlighting the importance of early awareness, access to eye care, and corrective interventions globally. According to the World Health Organization (WHO) and population-based studies, an estimated 1.8 to 2.1 billion people worldwide were affected as of 2020, with approximately 826 million experiencing uncorrected presbyopia, leading to significant functional vision loss.

Presbyopia Epidemiology Forecast Report Coverage

Expert Market Research's “Presbyopia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of presbyopia. It projects the future incidence and prevalence rates of presbyopia cases across various populations. The study covers age, gender, and type as major determinants of the presbyopia population. The report highlights patterns in the prevalence of presbyopia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on presbyopia epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Presbyopia Understanding: Disease Overview

Presbyopia is an age-related refractive condition characterized by the gradual loss of the eye’s ability to focus on near objects due to decreased lens elasticity. It typically manifests after 40 and progresses with age. The condition affects nearly all adults to varying degrees, regardless of gender or ethnicity. The symptoms include blurred near vision, eyestrain, and headaches during close-up tasks. Presbyopia is a natural part of the aging process and is distinct from myopia, hyperopia, or astigmatism, though it can coexist with these refractive errors.

Presbyopia Epidemiology Perspective

The presbyopia epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the presbyopia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for presbyopia and their trends. The presbyopia detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Presbyopia affects around 1.8 billion people globally, representing 24-25% of the world’s population and being the leading cause of near-vision impairment.
• Its prevalence increases sharply with age, and cases are projected to rise to approximately 2.1 billion by 2030 due to global population aging.
• For presbyopia, a meta-analysis found that female sex is significantly associated with earlier onset (adjusted OR ~1.02-1.45).
• Presbyopia affects all ethnicities, but Asians often experience earlier onset, while in Western populations, non-Hispanic Black and Mexican-American individuals show higher prevalence, influenced by genetics, environment, and healthcare access.

Country-wise Presbyopia Epidemiology Segment

The presbyopia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, presbyopia is a highly prevalent condition among adults. Approximately 128 million Americans, or nearly 90% of adults aged 45 and older, are affected. Studies indicate prevalence estimates ranging from 83% to 88.9% in this age group, highlighting the near-universal impact of age-related near-vision decline. Onset and severity may vary due to factors such as genetics, lifestyle, and healthcare access. This widespread occurrence emphasizes the need for awareness, timely diagnosis, and appropriate corrective measures to maintain quality of life among the aging population.

Presbyopia: Treatment Overview

Presbyopia management focuses on restoring near vision through optical, pharmacological, or surgical methods. Common interventions include corrective eyeglasses such as bifocals, progressive lenses, or reading glasses. Contact lenses, monovision or multifocal, are alternative options for patients seeking cosmetic or functional flexibility. Surgical treatments, including LASIK monovision, corneal inlays, and lens replacement procedures, are suitable for selected candidates. Emerging pharmacological therapies, such as miotic eye drops (e.g., pilocarpine formulations), provide temporary improvement in near vision by increasing depth of focus. Treatment choice depends on lifestyle, age, and visual demands.

Key Questions Answered

• What are the key findings of presbyopia epidemiology in the 8 major markets?
• What will be the total number of patients with presbyopia across the 8 major markets during the forecast period?
• What was the country-wise presbyopia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of presbyopia during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of presbyopia during the forecast period of 2025-2034?
• What are the currently available treatments for presbyopia?
• What are the disease risks, signs, symptoms, and unmet needs of presbyopia?

Scope of the Presbyopia Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of presbyopia based on several factors.
• Presbyopia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The presbyopia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.